Pharmacogenomics and Treatment of common diseases
- سال انتشار: 1395
- محل انتشار: اولین کنگره پزشکی شخصی
- کد COI اختصاصی: IPMCMED01_109
- زبان مقاله: انگلیسی
- تعداد مشاهده: 398
نویسندگان
Azad university of Damghan
Molecular Genetic Department School of Biological Science Tarbiat Modares University. Tehran, Iran
Patology Department of Baghiyyatollah-Azam Hospital, Tehran. Iran
Faculty of Biological Science. Tarbiat Modares University. Tehran, Iran
چکیده
Pharmacogenomics has been widely recognized as fundamental steps toward personalized medicine. The clinical utility and applications of pharmacogenomics is at present particularly evident in some therapeutic areas. For example, anticancer drugs, psychotropic, and anticoagulants, instead of the old fall. The following are some of the gains that had been achieved, listed. Among the most common diseases in the world, cardiovascular disease, kidney disease, and diabetic nephropathy. ACE inhibitor treatment is clearly Reno protective. Furthermore, the ACE I/D polymorphism is a useful test to predict the progression of type 1 or type 2 diabetic nephropathy. Angiotensin -converting enzyme (ACE) is an enzyme involved in the renin-angiotensin-aldosterone and kinin-kallikrien pathways involved in blood pressure control. ACE inhibitors are used to treat cardiovascular and renal diseases, including hypertension. The high inter-individual variability in circulating ACE levels is explained, in large part, by the ACE I/D polymorphism. The D allele of the ACE I/D polymorphism is clearly associated with increased risk of diabetic nephropathy. By contrast, the associations of the ACE I/D polymorphism with hypertension and cardiovascular disease have been inconsistent. The ACE I/D polymorphism is a useful test to predict the renoprotective effect of ACE inhibitor or angiotensin receptor blocker treatment in patients with kidney disease. There is currently no evidence to support a role of the ACE I/D polymorphism in predicting future risk of cardiovascular events or blood pressure response to ACE inhibitors in the absence of renal dysfunction.Among the selected pharmacogenes, two are nuclear hormone receptors, namely VDR and PXR. The role of nuclear receptors in renal diseases has been recently highlighted with an emphasis on carbohydrate metabolism, lipid metabolism, immune response and inflammation.کلیدواژه ها
ACE inhibitors, cardiovascular disease, kidney disease, diabetic nephropathyمقالات مرتبط جدید
- حقوق شهروندی با رویکرد حق سلامت و ارتقا کیفیت زندگی ایثارگران
- Positive Discrimination for War Veterans in International Documents: A Comprehensive Analysis
- حقوق شهروندی ایثارگران: ارتقاء شاخصهای اجتماعی، ورزشی و فرهنگی
- نقش دانش معلمی در تربیت حقوق شهروندی و ارتقا آگاهی دانش آموزان
- تحلیل حقوق شهروندی ایثارگران با رویکرد حق سلامت و ارتقا کیفیت زندگی
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.